1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. News
  7. Summary
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  05/20 04:00:00 pm EDT
1.930 CAD   +0.52%
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/19OPSENS SAVVYWIRE™ FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULTANEOUSLY PUBLISHED IN EUROINTERVENTION JOURNAL
AQ
05/19Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPSENS NAMED TO 2022 OTCQX BEST 50

01/24/2022 | 09:01am EDT

QUEBEC CITY, QC, Jan. 24, 2022 /CNW/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce it has been named to the 2022 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year, taking the sixth position.

"Opsens is proud to be part of the OTCQX Best 50. We have made great progress on many fronts in the last few months, despite the challenging environment. We are optimistic about the opportunities we see ahead of us," said Louis Laflamme, President and Chief Executive Officer of OpSens. "Importantly, our product development pathway for our new SavvyWire is on track following the successful completion of our clinical human study and submission to the FDA and Health Canada for regulatory clearance. We anticipate the agencies review of our applications and are preparing our organization for a successful product launch, upon regulatory clearance, which will allow OpSens to tap into this $5 billion market," concluded Louis Laflamme.

The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market.  The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year.  Companies in the 2022 OTCQX Best 50 were ranked based on their performance in 2021. 

For the complete 2022 OTCQX Best 50 ranking, visit https://www.otcmarkets.com/files/2022_OTCQX_Best_50.pdf.

The OTCQX Best Market offers transparent and efficient trading of established, investor-focused U.S. and global companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly on interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesion access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

SOURCE OPSENS Inc.

© Canada Newswire, source Canada Newswire English

All news about OPSENS INC.
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/19OPSENS SAVVYWIRE™ FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULT..
AQ
05/19Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Rece..
CI
05/18Opsens Announces Publication of New Optowire Data in Journal
MT
05/18Opsens announces publication in jscai of data supporting the correlation between the op..
AQ
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
04/13TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022
CI
04/13OPSENS : CFO Certification
PU
More news
Analyst Recommendations on OPSENS INC.
More recommendations
Financials
Sales 2022 36,6 M 28,5 M 28,5 M
Net income 2022 -7,29 M -5,68 M -5,68 M
Net Debt 2022 - - -
P/E ratio 2022 -28,6x
Yield 2022 -
Capitalization 209 M 163 M 163 M
Capi. / Sales 2022 5,72x
Capi. / Sales 2023 3,85x
Nbr of Employees 163
Free-Float 95,0%
Chart OPSENS INC.
Duration : Period :
Opsens Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPSENS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,93 CAD
Average target price 4,22 CAD
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Louis Laflamme President, Chief Executive Officer & Director
Robin Villeneuve Chief Financial Officer & Secretary
Alan W. Milinazzo Executive Chairman
Jean Lavigueur Independent Director
Denis L. Harrington Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OPSENS INC.-37.74%163
THERMO FISHER SCIENTIFIC-17.46%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644